Results 71 to 80 of about 40,760 (162)

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow, Amanda Binkley, Jessica Meisner, Samantha Huo, Matthew Hinton   +4 more
wiley   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

Antiviral therapy of chronic hepatitis C complicated by systemic cryoglobulinemic vasculitis

Журнал инфектологии, 2016
Literature analysis of published data on mechanisms of infection, disease progression and treatment of chronic hepatitis C, associated with systemic cryoglobulinemic vasculitis and kidney involvement is presented.
N. V. Dunaeva, V. E. Karev, O. A. Vorobyeva, A. V. Mazing, S. V. Lapin, A. V. Smirnov, D. A. Gusev   +6 more
doaj  

Effect of quercetin on the transport of ritonavir to the central nervous system in vitro and in vivo

Acta Pharmaceutica, 2016
The aim of this study was to identify an effective flavonoid that could improve the intracellular accumulation of ritonavir in human brain-microvascular endothelial cells (HBMECs). An in vivo experiment on Sprague-Dawley rats was then designed to further
Liang Gongwen, Li Na, Ma Liping, Qian Zhonglian, Sun Yuwen, Shi Luwen, Zhao Libo   +6 more
doaj   +1 more source

Ritonavir [PDF]

Reactions Weekly, 2020
  +4 more sources

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease
Background and Aim Simnotrelvir/ritonavir and nirmatrelvir/ritonavir are major treatments for COVID‐19, but their comparative efficacy and safety, especially in patients with moderate to severe COVID‐19, remain unclear.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
doaj   +1 more source

Evaluating Drug Interactions between Ritonavir and Opioid Analgesics: Implications from Physiologically Based Pharmacokinetic Simulation

Pharmaceuticals
Several commonly used opioid analgesics, such as fentanyl, sufentanil, alfentanil, and hydrocodone, are by report primarily metabolized by the CYP3A4 enzyme.
Liang Ni, Zhihai Cao, Jiakang Jiang, Wei Zhang, Wei Hu, Qian Zhang, Chaozhuang Shen, Xijing Chen, Liang Zheng   +8 more
doaj   +1 more source

Physiologically‐based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co‐administered with ritonavir

CPT: Pharmacometrics & Systems Pharmacology
GLS4 is a first‐in‐class hepatitis B virus (HBV) capsid assembly modulator (class I) that is co‐administered with ritonavir to maintain the anticipated concentration required for the effective antiviral activity of GLS4.
Zexu Sun, Nan Zhao, Ran Xie, Bo Jia, Junyu Xu, Lin Luo, Yulei Zhuang, Yuyu Peng, Xinchang Liu, Yingjun Zhang, Xia Zhao, Zhaoqian Liu, Yimin Cui   +12 more
doaj   +1 more source

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

Infection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N, Yu X, Li L, Yang P, Dong R, Huang Y, Ling X, Shentu Q, Yu W, Jiang S   +9 more
doaj  

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration .   +17 more
europepmc   +1 more source